Opinion: An economist’s change of heart: It’s time to regulate the prescription-drug middlemen
Pharmacy-benefit managers find ways to boost their bottom line at the expense of employers and patients I’ve studied the drug supply chain for years. Like many economists, I saw pharmacy-benefit managers (PBMs) as valuable actors in restraining drug prices, particularly when they went to bat for employer-based health plans. I’ve had a change of heart. While these